Is IMV Inc. (IMV.TO) a Buy, Sell, or Hold?
TSX : IMV.TO
IMV Inc.
$1.12 CAD
$0 (0.0%)
- Volume
- 15.76K
- Average Volume
- 254
- Market Capitalization
- $13.12M
- P/E Ratio
- -0.18
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $13.10
- Year Low
- $0.62
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.93
Company Overview
TSX
Andrew Hall
Biotechnology
Healthcare
IMV.TO
63
CA
CAD
Liquidity Metrics
-4.38
2.93
2.93
2.25
0.00
Sales & Valuation
-$
0.00
-1.01
-0.27
-4.13
Profitability
-$4.43
-$36.99M
0.00%
0.00%
-495.17%
-117.99%
P/E Metrics
-0.18
-0.02
-0.02
Analyst Price Target & Rating
0/5
7 Analysts
%
Financial Health Scores
-11.60
1/9
$18.17M
$31.35M
$37.95M
-$36.91M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Heather Hirsch | Vice President of Translational Research |
| Jeremy R. Graff | Chief Scientific Officer |
| Stephan Fiset | Vice President of Clinical Research |
| Jennifer Schmitke | Acting Chief Operating Officer |
| Linda Barabe | Senior Vice President of HR |
| Brittany Davison | Chief Accounting Officer, Corporation Sec. & Director |
Poll Results
No votes yet today — be the first to share your view!
About IMV Inc. (TSX:IMV.TO) Stock
IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers. Its leading investigational drug, maveropepimut-S, is a DPX-based immunotherapy designed to target cancer cells that express survivin. Maveropepimut-S is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and specific bladder, liver, and microsatellite instability-high tumors, with Phase I trials also active for breast cancer. Beyond its primary candidate, IMV is also advancing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, and is developing DPX-COVID-19 and ... DPX-RSV to address infectious diseases. Originally founded in 2000 as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018 and operates from its headquarters in Dartmouth, Canada.
Frequently Asked Questions
-
What is the current IMV Inc. (IMV.TO) stock price?
-
IMV Inc.(TSX:IMV.TO) stock price is $1.12 in the last trading session. During the trading session, IMV.TO stock reached the peak price of $13.1 while $0.62 was the lowest point it dropped to. The percentage change in IMV.TO stock occurred in the recent session was 0.0% while the dollar amount for the price change in IMV.TO stock was $0.
-
IMV.TO's industry and sector of operation?
-
The TSX listed IMV.TO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of IMV.TO?
-
Heather Hirsch | Vice President of Translational Research
Jeremy R. Graff | Chief Scientific Officer
Stephan Fiset | Vice President of Clinical Research
Jennifer Schmitke | Acting Chief Operating Officer
Linda Barabe | Senior Vice President of HR -
How many employees does IMV.TO have?
-
Number of IMV.TO employees currently stands at 63. IMV.TO operates from 130 Eileen Stubbs Avenue, Dartmouth, NS B3B 2C4, CA.
-
Link for IMV.TO official website?
-
Official Website of IMV.TO is: https://www.imv-inc.com
-
How do I contact IMV.TO?
-
IMV.TO could be contacted at phone #19024921819 and can also be accessed through its website. IMV.TO operates from 130 Eileen Stubbs Avenue, Dartmouth, NS B3B 2C4, CA.
-
How many shares of IMV.TO are traded daily?
-
The average number of IMV.TO shares traded daily for last 3 months was 254.
-
What is the market cap of IMV.TO currently?
-
The market value of IMV.TO currently stands at $13.12M with its latest stock price at $1.12